

Chair Nosse, Vice-Chair Goodwin, Vice-Chair Nelson, and Members of the Committee:

I strongly support HB 2574, which requires hospitals to adopt policies and procedures to ensure the provision of human immunodeficiency virus post-exposure prophylactic drugs or therapies. This bill is crucial in ensuring that patients who have been exposed to HIV have access to the necessary treatments without any financial barriers.

It is imperative that we take proactive measures to prevent the spread of HIV and ensure that patients receive prompt treatment in the event of possible exposure. The requirement for the Oregon Health Authority to prescribe a formula to determine the number of five-day supplies of prophylactic drugs or therapies needed by type A and type B hospitals and to provide these supplies at no cost to the hospital is commendable. This will not only benefit patients but also ensure that hospitals are equipped with the necessary resources to provide proper care.

The prohibition of health benefit plans from imposing copayments, coinsurance, or other cost-sharing on the coverage of human immunodeficiency virus post-exposure prophylactic drugs or therapies is a step in the right direction in terms of reducing the financial burden on patients.

In conclusion, I believe that this bill will help to improve access to HIV post-exposure prophylactic drugs or therapies and ultimately help to prevent the spread of HIV. I strongly encourage the passage of HB 2574 as it will be a positive step towards a more equitable and accessible healthcare system for all.

Sincerely,

*Devon Lawson-McCourt*

Vida, Oregon